Nitya Bakshi, MBBS, MS
she/her/hers
Associate Professor of PediatricsDownloadHi-Res Photo
Cards
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Titles
Associate Professor of Pediatrics
Biography
Appointments
Pediatric Hematology & Oncology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- MS
- University of Pittsburgh, Clinical Research (2014)
- MBBS
- Christian Medical College, Vellore (2007)
Research
Overview
Medical Research Interests
Anemia, Sickle Cell; Chronic Pain; Integrative Medicine; Patient Reported Outcome Measures; Research Support, N.I.H., Extramural; Sickle Cell Trait; Support of Research
ORCID
0000-0002-0876-9506
Research at a Glance
Yale Co-Authors
Frequent collaborators of Nitya Bakshi's published research.
Publications Timeline
A big-picture view of Nitya Bakshi's research output by year.
Research Interests
Research topics Nitya Bakshi is interested in exploring.
Lakshmanan Krishnamurti, MD
Inci Yildirim, MD, PhD, MSc
46Publications
774Citations
Anemia, Sickle Cell
Chronic Pain
Patient Reported Outcome Measures
Publications
2024
Long‐term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis
Arnold S, Bakshi N, Ross D, Smith C, Sinha C, Veludhandi A, Dutreuil V, Bai S, Meacham L, Guilcher G, Bhatia M, Abraham A, Kasow K, Haight A, Rassi F, Stenger E, Lipscomb J, Krishnamurti L. Long‐term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis. American Journal Of Hematology 2024, 99: 2037-2040. PMID: 39105410, DOI: 10.1002/ajh.27436.Peer-Reviewed Original ResearchAltmetricImpact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain
Korman R, Hatabah D, Brown L, Harris F, Wilkinson H, Rees C, Bakshi N, Archer D, Dampier C, Morris C. Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain. Blood Advances 2024, 8: 3267-3271. PMID: 38527291, PMCID: PMC11226964, DOI: 10.1182/bloodadvances.2023012209.Peer-Reviewed Original ResearchAltmetricHigh-impact chronic pain in sickle cell disease: insights from the Pain in Sickle Cell Epidemiology Study (PiSCES)
Jagtiani A, Chou E, Gillespie S, Liu K, Krishnamurti L, McClish D, Smith W, Bakshi N. High-impact chronic pain in sickle cell disease: insights from the Pain in Sickle Cell Epidemiology Study (PiSCES). Pain 2024, 165: 2364-2369. PMID: 38787626, PMCID: PMC11404329, DOI: 10.1097/j.pain.0000000000003262.Peer-Reviewed Original ResearchAltmetricConceptsHigh-impact chronic painSickle Cell Epidemiology StudyChronic painProportion of daysUS National Pain StrategySickle cell diseaseNational Pain StrategySelf-care activitiesEpidemiological studiesHigher levels of stressMean pain intensityCohort of individualsPain interferenceLevels of stressPhysical functionHealth outcomesHealthcare utilizationPhysical healthPain strategiesPain burdenPain intensityPain diaryCell diseaseDiary daysAffected subgroups
2023
A cognitive–behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized, controlled, multicenter trial
Palermo T, Lalloo C, Zhou C, Dampier C, Zempsky W, Badawy S, Bakshi N, Ko Y, Nishat F, Stinson J. A cognitive–behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized, controlled, multicenter trial. Pain 2023, 165: 164-176. PMID: 37733479, PMCID: PMC10723646, DOI: 10.1097/j.pain.0000000000003009.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSickle cell diseaseEducation controlSickle Cell Disease PainEvidence-based cognitive behavioral therapySickle cell painAverage pain intensitySignificant healthcare costsCognitive behavioral therapy programCognitive behavioral therapyDigital health interventionsPain daysSCD clinicSecondary outcomesCommon complicationDisease painMulticenter trialPain intensityPain interferenceChronic painPain interventionsEffective implementation strategiesGlobal ImpressionCell diseasePsychosocial distressPainPatient-reported outcomes in children with sickle cell disease at presentation for an acute pain episode
Bakshi N, Liu Z, Gillespie S, Keesari R, Leake D, Khemani K, Kumari P, Rees C, Dampier C, Morris C. Patient-reported outcomes in children with sickle cell disease at presentation for an acute pain episode. Blood Advances 2023, 7: 5103-5107. PMID: 36322873, PMCID: PMC10477437, DOI: 10.1182/bloodadvances.2021006794.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsSickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial
Rees C, Brousseau D, Cohen D, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi C, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman K, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper T, Vichinsky E, Morris C. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials 2023, 24: 538. PMID: 37587492, PMCID: PMC10433602, DOI: 10.1186/s13063-023-07538-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPediatric Emergency Care Applied Research NetworkSickle cell disease treatmentVaso-occlusive episodesSickle cell diseaseSTART trialArginine therapyIntravenous arginineLoading doseNormal saline three timesYoung adultsBlood Institute guidelinesParental opioid usePlacebo loading doseSubstantial illness burdenDisease-modifying therapiesPatient-reported outcomesDisease treatmentPhase 3Emergency medicine providersSaline three timesMulticenter research networkResearch NetworkIntravenous opioidsLast doseStudy drugSex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease
Astles R, Liu Z, Gillespie S, Lai K, Maillis A, Morris C, Lane P, Krishnamurti L, Bakshi N. Sex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease. PAIN Reports 2023, 8: e1084. PMID: 37559677, PMCID: PMC10409410, DOI: 10.1097/pr9.0000000000001084.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHigher health care utilizationHealth care utilizationSickle cell diseaseAcute pain trajectoriesPain intensity scoresEmergency departmentPain trajectoriesPain episodesCell diseaseHigher mean pain intensity scoreIntensity scoresMean pain intensity scoreAcute pain episodesFrequency of painAdolescent female patientsFuture prospective studiesElectronic health recordsIntranasal opioidsPain frequencyAcute painPain intensityRetrospective reviewCare utilizationFemale patientsProspective studyParental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation
Sinha C, Meacham L, Bakshi N, Ross D, Krishnamurti L. Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2023, 70: e30276. PMID: 37051746, PMCID: PMC10544372, DOI: 10.1002/pbc.30276.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationRisk of infertilitySickle cell diseaseStem cell transplantationFertility preservationCell transplantationCell diseaseMajor long-term complicationPrimary caregiversIdentical related donorsDisease-free survivalFertility preservation optionsFertility preservation proceduresLong-term complicationsHuman leukocyte antigenConditioning regimenHost diseaseRelated donorsLeukocyte antigenPreservation optionsHCT physiciansSurvival rateAvailable HLAEleven participantsInfertility488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study
Khemani K, Stenger E, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Krishnamurti L. 488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Transplantation And Cellular Therapy 2023, 29: s366. DOI: 10.1016/s2666-6367(23)00556-0.Peer-Reviewed Original Research
2022
Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease
Bakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C, Sanders K, Peddineni M, Gillespie S, Keesari R, Krishnamurti L. Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease. Pediatric Blood & Cancer 2022, 70: e30046-e30046. PMID: 36322607, PMCID: PMC9820671, DOI: 10.1002/pbc.30046.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHematopoietic cell transplantPatient-reported outcomesSickle cell diseaseYear post-HCTPost-HCTExperimental pain sensitivitySickle cell anemiaCell transplantPain thresholdPain sensitivityCell diseaseCorrelates of painPressure pain thresholdHealth-related qualityCold pain thresholdAssessment of painPsychological factorsUnderstanding of painEffect sizePain assessmentObservational studySevere genotypePainCell anemiaOptional substudies
Clinical Trials
Current Trials
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
HIC ID2000037926RoleSub InvestigatorPrimary Completion Date04/28/2031Recruiting ParticipantsGenderBothAge5 years - 60 yearsA Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
HIC ID2000034938RoleSub InvestigatorPrimary Completion Date02/01/2027Recruiting ParticipantsA Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsPediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
HIC ID2000034939RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
HIC ID2000032775RoleSub InvestigatorPrimary Completion Date03/31/2031Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Sickle Cell Disease
Learn More on Yale MedicineChronic Pain
Learn More on Yale MedicineChronic Pelvic Pain in Women
Learn More on Yale MedicineChronic Stress
Learn More on Yale Medicine
Board Certifications
Pediatric Hematology-Oncology
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2015
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2011
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.